Northwest Biotherapeutics Inc. (OTCQB:NWBO), a biotechnology company focused on developing personalized cancer vaccines, announced the results of its annual stockholders' meeting held on June 29, 2024. Shareholders voted on several key proposals, including the re-election of board members, executive compensation, and the ratification of the company's independent auditor.
At the meeting, a quorum was present with 961,690,911 shares represented, accounting for 77.48% of the total voting power. Shareholders approved the re-election of Dr. Alton L. Boynton and Ambassador J. Cofer Black as Class I members of the Board of Directors for another three-year term. The results showed strong support for both directors, with Dr. Boynton receiving 94.04% of the vote and Ambassador Black receiving 93.01%.
Additionally, the appointment of Cherry Bekaert LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with 92.73% of the votes in favor.
Stockholders also ratified option awards made in 2020 to named executive officers and non-executive Directors on the Board of Directors. These awards had previously been approved in advisory votes at the 2021 Annual Meeting and ratified at the 2022 Annual Meeting. The ratification of the named executive officer option awards received 88.13% approval, while the non-executive director option awards received 88.05% approval.
Furthermore, an advisory vote on the company's 2023 executive compensation was approved with 87.37% of the votes in favor, indicating stockholder satisfaction with the company's executive compensation practices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.